James E Polli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4920910/publications.pdf

Version: 2024-02-01

137 papers	5,504 citations	101543 36 h-index	91884 69 g-index
140 all docs	140 docs citations	140 times ranked	4992 citing authors

#	Article	IF	Citations
1	Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharmaceutical Research, 2002, 19, 921-925.	3.5	460
2	Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. European Journal of Pharmaceutical Sciences, 2002, 16, 237-246.	4.0	439
3	Methods to Compare Dissolution Profiles and a Rationale for Wide Dissolution Specifications for Metoprolol Tartrate tabletsâ€. Journal of Pharmaceutical Sciences, 1997, 86, 690-700.	3.3	266
4	Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally Sampled Pharmacophore Approach. Current Computer-Aided Drug Design, 2011, 7, 10-22.	1.2	210
5	Effect of Common Excipients on Caco-2 Transport of Low-Permeability Drugs. Journal of Pharmaceutical Sciences, 2001, 90, 1776-1786.	3.3	167
6	Apical Sodium Dependent Bile Acid Transporter (ASBT, SLC10A2):Â A Potential Prodrug Target. Molecular Pharmaceutics, 2006, 3, 223-230.	4.6	150
7	The solute carrier family 10 (SLC10): Beyond bile acid transport. Molecular Aspects of Medicine, 2013, 34, 252-269.	6.4	145
8	Rapid Identification of P-glycoprotein Substrates and Inhibitors. Drug Metabolism and Disposition, 2006, 34, 1976-1984.	3.3	136
9	The Use of BDDCS in Classifying the Permeability of Marketed Drugs. Pharmaceutical Research, 2008, 25, 483-488.	3.5	124
10	In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms. AAPS Journal, 2008, 10, 289-299.	4.4	117
11	Surfactant-mediated dissolution: Contributions of solubility enhancement and relatively low micelle diffusivity. Journal of Pharmaceutical Sciences, 2004, 93, 2064-2075.	3.3	116
12	Influence of passive permeability on apparent P-glycoprotein kinetics. Pharmaceutical Research, 2000, 17, 1456-1460.	3.5	111
13	Increased Acyclovir Oral Bioavailability via a Bile Acid Conjugate. Molecular Pharmaceutics, 2004, 1, 40-48.	4.6	110
14	Computational Models for Drug Inhibition of the Human Apical Sodium-Dependent Bile Acid Transporter. Molecular Pharmaceutics, 2009, 6, 1591-1603.	4.6	89
15	Structureâ€“Activity Relationship for FDA Approved Drugs As Inhibitors of the Human Sodium Taurocholate Cotransporting Polypeptide (NTCP). Molecular Pharmaceutics, 2013, 10, 1008-1019.	4.6	86
16	Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. International Journal of Pharmaceutics, 2000, 200, 41-51.	5.2	77
17	3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration. Clinical and Translational Science, 2021, 14, 1659-1680.	3.1	77
18	Novel Approach to the Analysis of in Vitroâ€“in Vivo Relationships**Presented in part at the Ninth Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists, San Diego, CA, November 1994.. Journal of Pharmaceutical Sciences, 1996, 85, 753-760.	3.3	76

#	Article	IF	Citations
19	Prediction of dissolutionâ€“absorption relationships from a dissolution/Caco-2 system. International Journal of Pharmaceutics, 1999, 177, 117-125.	5.2	73
20	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Ketoprofen. Journal of Pharmaceutical Sciences, 2012, 101, 3593-3603.	3.3	70
21	Generic lamotrigine versus brandâ€name <scp>Lamictal</scp> bioequivalence in patients with epilepsy: A field test of the <scp>FDA</scp> bioequivalence standard. Epilepsia, 2015, 56, 1415-1424.	5.1	68
22	Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharmaceutical Research, 2003, 20, 757-764.	3.5	63
23	Computational Models to Assign Biopharmaceutics Drug Disposition Classification from Molecular Structure. Pharmaceutical Research, 2007, 24, 2249-2262.	3.5	61
24	The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance. Journal of Pharmaceutical Sciences, 2014, 103, 3377-3397.	3.3	60
25	Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond. AAPS Journal, 2008, 10, 373-379.	4.4	55
26	Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system. AAPS PharmSci, 1999, 1, 27-38.	1.3	52
27	Interaction of Native Bile Acids with Human Apical Sodium-Dependent Bile Acid Transporter (hASBT): Influence of Steroidal Hydroxylation Pattern and C-24 Conjugation. Pharmaceutical Research, 2006, 23, 1451-1459.	3.5	50
28	Lipid composition effect on permeability across PAMPA. European Journal of Pharmaceutical Sciences, 2006, 29, 259-268.	4.0	50
29	Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids. Carcinogenesis, 2015, 36, 1193-1200.	2.8	49
30	Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir. Journal of Pharmaceutical Sciences, 2016, 105, 996-1005.	3.3	43
31	Impact of Biopharmaceutics Classification System-Based Biowaivers. Molecular Pharmaceutics, 2010, 7, 1539-1544.	4.6	42
32	Development of Stably Transfected Monolayer Overexpressing the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT). Pharmaceutical Research, 2005, 22, 1269-1280.	3.5	41
33	Weight Uniformity of Split Tablets Required by a Veterans Affairs Policy. Journal of Managed Care Pharmacy, 2003, 9, 401-407.	2.2	39
34	Comparison of Drug Permeabilities and BCS Classification: Three Lipid-Component PAMPA System Method versus Caco-2 Monolayers. AAPS Journal, 2010, 12, 238-241.	4.4	38
35	Methods to Compare Dissolution Profiles. Drug Information Journal, 1996, 30, 1113-1120.	0.5	36
36	Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities. , 1998, 15, 47-52.		36

#	Article	IF	Citations
37	Novel Inhibitors of Human Organic Cation/Carnitine Transporter (hOCTN2) via Computational Modeling and In Vitro Testing. Pharmaceutical Research, 2009, 26, 1890-1900.	3.5	36
38	Considerations for a Pediatric Biopharmaceutics Classification System (BCS): Application to Five Drugs. AAPS PharmSciTech, 2014, 15, 601-611.	3.3	35
39	Synthesis and In Vitro Evaluation of Gabapentin Prodrugs that Target the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT). Journal of Pharmaceutical Sciences, 2011, 100, 1184-1195.	3.3	33
40	Bias in Estimation of Transporter Kinetic Parameters from Overexpression Systems: Interplay of Transporter Expression Level and Substrate Affinity. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 133-144.	2.5	32
41	Quantitative Structure Activity Relationship for Inhibition of Human Organic Cation/Carnitine Transporter. Molecular Pharmaceutics, 2010, 7, 2120-2131.	4.6	31
42	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine. Journal of Pharmaceutical Sciences, 2015, 104, 3289-3298.	3.3	31
43	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Amoxicillin Trihydrate. Journal of Pharmaceutical Sciences, 2017, 106, 2930-2945.	3.3	31
44	Structural requirements of bile acid transporters: C-3 and C-7 modifications of steroidal hydroxyl groups. European Journal of Pharmaceutical Sciences, 2012, 46, 86-99.	4.0	30
45	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Fluconazole. Journal of Pharmaceutical Sciences, 2014, 103, 3843-3858.	3.3	29
46	Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition. European Journal of Pharmaceutical Sciences, 2015, 66, 1-9.	4.0	29
47	Effects of Commonly Used Excipients on the Expression of CYP3A4 in Colon and Liver Cells. Pharmaceutical Research, 2010, 27, 1703-1712.	3.5	27
48	Uptake of Pramipexole by Human Organic Cation Transporters. Molecular Pharmaceutics, 2010, 7, 1342-1347.	4.6	27
49	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril. Journal of Pharmaceutical Sciences, 2017, 106, 1933-1943.	3.3	27
50	Inhibition Requirements of the Human Apical Sodium-Dependent Bile Acid Transporter (hASBT) Using Aminopiperidine Conjugates of glutamyl-Bile Acids. Pharmaceutical Research, 2009, 26, 1665-1678.	3.5	26
51	Synthesis and in vitro evaluation of bile acid prodrugs of floxuridine to target the liver. International Journal of Pharmaceutics, 2014, 475, 597-604.	5.2	26
52	Ion pair-mediated transport of metoprolol across a three lipid-component PAMPA system. Journal of Controlled Release, 2006, 116, 50-57.	9.9	25
53	Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets. Molecular Pharmaceutics, 2015, 12, 2436-2443.	4.6	25
54	A substrate pharmacophore for the human sodium taurocholate co-transporting polypeptide. International Journal of Pharmaceutics, 2015, 478, 88-95.	5.2	25

#	Article	IF	Citations
55	Novel direct curve comparison metrics for bioequivalence. , 2001, 18, 734-741.		24
56	Influence of Charge and Steric Bulk in the C-24 Region on the Interaction of Bile Acids with Human Apical Sodium-Dependent Bile Acid Transporter. Molecular Pharmaceutics, 2006, 3, 282-292.	4.6	24
57	Synthesis and in vitro evaluation of potential sustained release prodrugs via targeting ASBT. International Journal of Pharmaceutics, 2010, 396, 111-118.	5.2	24
58	Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). Pharmaceutical Research, 2018, 35, 243.	3.5	24
59	Molecular Switch Controlling the Binding of Anionic Bile Acid Conjugates to Human Apical Sodium-Dependent Bile Acid Transporter. Journal of Medicinal Chemistry, 2010, 53, 4749-4760.	6.4	23
60	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Levetiracetam. Journal of Pharmaceutical Sciences, 2015, 104, 2676-2687.	3.3	23
61	Optimizing Clinical Drug Product Performance: Applying Biopharmaceutics Risk Assessment Roadmap (BioRAM) and the BioRAM Scoring Grid. Journal of Pharmaceutical Sciences, 2016, 105, 3243-3255.	3.3	23
62	Evaluation of direct curve comparison metrics applied to pharmacokinetic profiles and relative bioavailability and bioequivalence. , 1997, 14, 1363-1369.		22
63	Identification of inhibitor concentrations to efficiently screen and measure inhibition Ki values against solute carrier transporters. European Journal of Pharmaceutical Sciences, 2010, 41, 43-52.	4.0	22
64	Structural Determinants for Transport across the Intestinal Bile Acid Transporter Using C-24 Bile Acid Conjugates. Molecular Pharmaceutics, 2010, 7, 2240-2254.	4.6	22
65	Prediction of positive food effect: Bioavailability enhancement of BCS class II drugs. International Journal of Pharmaceutics, 2016, 506, 110-115.	5.2	22
66	Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity. Pharmaceutical Research, 2018, 35, 204.	3.5	22
67	in Vitro-in Vivo Relationships of Several â€œImmediateâ€•Release Tablets Containing a Low Permeability Drug. Advances in Experimental Medicine and Biology, 1997, 423, 191-198.	1.6	20
68	In Vivo Performance of a Novel Fluorinated Magnetic Resonance Imaging Agent for Functional Analysis of Bile Acid Transport. Molecular Pharmaceutics, 2014, 11, 1575-1582.	4.6	20
69	Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice. Oncotarget, 2018, 9, 25572-25585.	1.8	20
70	Synthesis and Evaluation of Bile Acidâ€“Ribavirin Conjugates as Prodrugs to Target the Liver. Journal of Pharmaceutical Sciences, 2015, 104, 2864-2876.	3.3	19
71	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Folic Acid. Journal of Pharmaceutical Sciences, 2017, 106, 3421-3430.	3.3	19
72	Multidrug and toxin extrusion proteins mediate cellular transport of cadmium. Toxicology and Applied Pharmacology, 2017, 314, 55-62.	2.8	19

#	Article	IF	Citations
73	Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. Drug Metabolism and Disposition, 2016, 44, 489-494.	3.3	18
74	Targeting Drug Transporters â€“ Combining In Silico and In Vitro Approaches to Predict In Vivo. Methods in Molecular Biology, 2010, 637, 65-103.	0.9	17
75	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. Journal of Pharmaceutical Sciences, 2016, 105, 1362-1369.	3.3	17
76	â€˜PAVLOVIANâ€™ FOOD EFFECT ON THE ENTEROHEPATIC RECIRCULATION OF PIROXICAM. , 1996, 17, 635-641.		16
77	Method to Screen Substrates of Apical Sodium-Dependent Bile Acid Transporter. AAPS Journal, 2008, 10, 596-605.	4.4	16
78	Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2. Journal of Pharmaceutical Sciences, 2011, 100, 3802-3816.	3.3	16
79	A Substrate Pharmacophore for the Human Organic Cation/Carnitine Transporter Identifies Compounds Associated with Rhabdomyolysis. Molecular Pharmaceutics, 2012, 9, 905-913.	4.6	16
80	Metformin Disrupts Bile Acid Efflux by Repressing Bile Salt Export Pump Expression. Pharmaceutical Research, 2020, 37, 26.	3.5	16
81	Evaluation of Excipient Risk in BCS Class I and III Biowaivers. AAPS Journal, 2022, 24, 20.	4.4	16
82	Reliability of Inhibition Models to Correctly Identify Type of Inhibition. Pharmaceutical Research, 2010, 27, 2433-2445.	3.5	15
83	Structural Requirements of the ASBT by 3D-QSAR Analysis Using Aminopyridine Conjugates of Chenodeoxycholic Acid. Bioconjugate Chemistry, 2010, 21, 2038-2048.	3.6	15
84	Mechanistic interpretation of conventional Michaelisâ€“Menten parameters in a transporter system. European Journal of Pharmaceutical Sciences, 2014, 64, 44-52.	4.0	15
85	Pigâ€gene mutation database. Environmental and Molecular Mutagenesis, 2019, 60, 759-762.	2.2	15
86	Utility of Films to Anticipate Effect of Drug Load and Polymer on Dissolution Performance from Tablets of Amorphous Itraconazole Spray-Dried Dispersions. AAPS PharmSciTech, 2019, 20, 331.	3.3	14
87	Fast liquid chromatography-tandem mass spectrometry method for simultaneous determination of eight antiepileptic drugs and an active metabolite in human plasma using polarity switching and timed selected reaction monitoring. Journal of Pharmaceutical and Biomedical Analysis, 2019, 176, 112816.	2.8	14
88	Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatographyâ€“Inductively Coupled Plasmaâ€“Mass Spectrometric Approach. Molecular Pharmaceutics, 2019, 16, 1272-1281.	4.6	14
89	Similarity of dissolution profiles from biorelevant media: Assessment of interday repeatability, interanalyst repeatability, and interlaboratory reproducibility using ibuprofen and ketoconazole tablets. European Journal of Pharmaceutical Sciences, 2021, 156, 105573.	4.0	14
90	ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. Molecular Pharmaceutics, 2020, 17, 361-372.	4.6	13

#	Article	IF	Citations
91	Characterization of Grades of HPMCAS Spray Dried Dispersions of Itraconazole Based on Supersaturation Kinetics and Molecular Interactions Impacting Formulation Performance. Pharmaceutical Research, 2020, 37, 192.	3.5	13
92	The effects of spray drying, HPMCAS grade, and compression speed on the compaction properties of itraconazole-HPMCAS spray dried dispersions. European Journal of Pharmaceutical Sciences, 2020, 155, 105556.	4.0	12
93	Biomimetic Artificial Membrane Permeability Assay over Franz Cell Apparatus Using BCS Model Drugs. Pharmaceutics, 2020, 12, 988.	4.5	12
94	Characterization of Dexloxiglumide in vitro Biopharmaceutical Properties and Active Transport. Journal of Pharmaceutical Sciences, 2003, 92, 1968-1980.	3.3	11
95	Why we should be vigilant: Drug cytotoxicity observed with in vitro transporter inhibition studies. Biochemical Pharmacology, 2010, 80, 1087-1092.	4.4	11
96	Chemical Substituent Effect on Pyridine Permeability and Mechanistic Insight from Computational Molecular Descriptors. Molecular Pharmaceutics, 2006, 3, 745-755.	4.6	10
97	Design and Evaluation of a Novel Trifluorinated Imaging Agent for Assessment of Bile Acid Transport Using Fluorine Magnetic Resonance Imaging. Journal of Pharmaceutical Sciences, 2014, 103, 3782-3792.	3.3	10
98	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine. Journal of Pharmaceutical Sciences, 2021, 110, 1935-1947.	3.3	10
99	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate. Journal of Pharmaceutical Sciences, 2020, 109, 1846-1862.	3.3	10
100	Dependence of In Vitro-In Vivo Correlation Analysis Acceptability on Model Selections. Pharmaceutical Development and Technology, 1999, 4, 89-96.	2.4	9
101	Design and Characterization of a Novel Fluorinated Magnetic Resonance Imaging Agent for Functional Analysis of Bile Acid Transporter Activity. Pharmaceutical Research, 2013, 30, 1240-1251.	3.5	9
102	Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey. Annals of the New York Academy of Sciences, 2017, 1407, 26-38.	3.8	9
103	Identification of Novel Nonsteroidal Compounds as Substrates or Inhibitors of hASBT. Journal of Pharmaceutical Sciences, 2012, 101, 116-126.	3.3	8
104	Quantification of Lamotrigine in Patient Plasma Using a Fast Liquid Chromatographyâ€“Tandem Mass Spectrometry Method With Backflush Technology. Therapeutic Drug Monitoring, 2015, 37, 188-197.	2.0	8
105	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metformin Hydrochloride. Journal of Pharmaceutical Sciences, 2021, 110, 1513-1526.	3.3	8
106	Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy. Epilepsy and Behavior, 2019, 90, 197-203.	1.7	7
107	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride. Journal of Pharmaceutical Sciences, 2020, 109, 2654-2675.	3.3	7
108	Research and Education Needs for Complex Generics. Pharmaceutical Research, 2021, 38, 1991-2001.	3.5	7

#	Article	IF	Citations
109	Lack of an Effect of Polysorbate 80 on Intestinal Drug Permeability in Humans. Pharmaceutical Research, 2022, 39, 1881-1890.	3.5	7
110	Novel Metrics to Compare Dissolution Profiles. Pharmaceutical Development and Technology, 2002, 7, 257-265.	2.4	6
111	Impact of Impurity on Kinetic Estimates from Transport and Inhibition Studies. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 296-305.	2.5	6
112	In Vivo Magnetic Resonance Imaging to Detect Biliary Excretion of 19F-Labeled Drug in Mice. Drug Metabolism and Disposition, 2011, 39, 736-739.	3.3	6
113	Putative Irreversible Inhibitors of the Human Sodium-Dependent Bile Acid Transporter (hASBT;) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Pharmaceutical Research, 2012, 29, 1821-1831.	3.5	6
114	Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport. Journal of Visualized Experiments, 2016, , .	0.3	6
115	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Sitagliptin Phosphate Monohydrate. Journal of Pharmaceutical Sciences, 2022, 111, 2-13.	3.3	6
116	Prediction of in vitro drug dissolution into fasted-state biorelevant media: Contributions of solubility enhancement and relatively low colloid diffusivity. European Journal of Pharmaceutical Sciences, 2022, 174, 106210.	4.0	6
117	Structural Requirements of the Human Sodium-Dependent Bile Acid Transporter (hASBT): Role of 3- and 7-OH Moieties on Binding and Translocation of Bile Acids. Molecular Pharmaceutics, 2014, 11, 588-598.	4.6	5
118	Reply to â€œOn the Effect of Common Excipients on the Oral Absorption of Class 3 Drugsâ€• Journal of Pharmaceutical Sciences, 2016, 105, 1355-1357.	3.3	5
119	Indinavir Alters the Pharmacokinetics of Lamivudine Partially via Inhibition of Multidrug and Toxin Extrusion Protein 1 (MATE1). Pharmaceutical Research, 2018, 35, 14.	3.5	5
120	Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride. Journal of Pharmaceutical Sciences, 2018, 107, 1761-1772.	3.3	5
121	Authorized Generic Drugs: an Overview. AAPS PharmSciTech, 2018, 19, 2450-2458.	3.3	5
122	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron. Journal of Pharmaceutical Sciences, 2019, 108, 3157-3168.	3.3	5
123	Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate. Molecular Pharmaceutics, 2021, 18, 1544-1557.	4.6	5
124	Prediction of In Vitro Drug Dissolution into Fed-state Biorelevant Media: Contributions of Solubility Enhancement and Relatively Low Colloid Diffusivity. European Journal of Pharmaceutical Sciences, 2022, 173, 106179.	4.0	5
125	Attenuated Accumulation of Novel Fluorine (¹⁹F)-Labeled Bile Acid Analogues in Gallbladders of Fibroblast Growth Factor-15 (FGF15)-Deficient Mice. Molecular Pharmaceutics, 2018, 15, 4827-4834.	4.6	4
126	A 19F magnetic resonance imaging-based diagnostic test for bile acid diarrhea. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2019, 32, 163-171.	2.0	3

#	Article	IF	Citations
127	Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy. Epilepsy and Behavior, 2020, 105, 106936.	1.7	3
128	Characterization of Dissolution-Permeation System using Hollow Fiber Membrane Module and Utility to Predict in Vivo Drug Permeation Across BCS Classes. Journal of Pharmaceutical Sciences, 2022, 111, 3075-3087.	3.3	3
129	Release of levetiracetam from extended-release tablets that appear intact in patient stool. Seizure: the Journal of the British Epilepsy Association, 2016, 40, 7-9.	2.0	2
130	Human Intestinal Cellular Characteristics and Drug Permeability. , 2004, , 163-180.		2
131	Sources of dissolution variability into biorelevant media. International Journal of Pharmaceutics, 2022, 620, 121745.	5.2	2
132	Evaluation of a novel tablet splitter. Journal of the American Pharmacists Association: JAPhA, 2007, 47, 185-187.	1.5	1
133	Gordon L. Amidon: Very Sustained Drug Absorption. Journal of Pharmaceutical Sciences, 2015, 104, 2650-2663.	3.3	1
134	Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy. Pharmaceutical Research, 2020, 37, 60.	3.5	1
135	Phrygian Cap Appearance of a Mouse Gallbladder on Magnetic Resonance Imaging. Journal of Veterinary Science & Medical Diagnosis, 2013, 02, .	0.0	0
136	Lack of association between generic brittleness and neuropsychiatric measures in patients with epilepsy. Epilepsy and Behavior, 2022, 128, 108587.	1.7	0
137	Comparison of a single pharmaceutical surfactant versus intestinal biorelevant media for etravirine dissolution: Role and impact of micelle diffusivity. International Journal of Pharmaceutics, 2022, 624, 122015.	5.2	0